** Drugmaker Incyte's INCY.O shares rise 4.4% to $79.69
** INCY said on Sunday its experimental blood cancer treatment showed it could target and remove cancer cells while leaving healthy cells intact, potentially restoring normal blood production
** The therapy treats a group of blood disorders where a specific gene mutation causes blood cells to multiply uncontrollably
** 86% of patients on higher doses of the experimental therapy showed significant improvement in blood cell counts, with most (82%) achieving complete normalization of their previously elevated platelet levels
** INCY plans to meet with regulators and aims to start late-stage testing by early 2026
** Including session's moves, INCY stock down up 0.9% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。